東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

IL-6 signals through pStat3 to preve...

Goodman, Wendy Ann.

FindBook

Google Book

Amazon

博客來

IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells./
作者:	Goodman, Wendy Ann.
面頁冊數:	123 p.
附註:	Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2045.
Contained By:	Dissertation Abstracts International72-04B.
標題:	Health Sciences, Pathology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3446480
ISBN:	9781124505602

IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells.
Goodman, Wendy Ann.

IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells. - 123 p.

Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2045.

Thesis (Ph.D.)--Case Western Reserve University, 2011.

Human autoimmune diseases such as psoriasis, multiple sclerosis, and rheumatoid arthritis are characterized by systemic T cell dysfunction, resulting in chronically activated Th1 and Th17 cells which are insufficiently suppressed by regulatory T cells. The data presented herein demonstrate that the pro-inflammatory cytokine IL-6 directly inhibits human regulatory T cell function, similar to its functions in the mouse. IL-6 is over-expressed in tissue and serum of patients with autoimmune diseases and is produced in high amounts by dermal dendritic cells and endothelial cells in the lesional skin of psoriasis patients. Upon T cell entry to the lesional skin, cells are exposed to high levels of IL-6, which likely contribute to their escape from regulation by Treg cells. We sought to determine the mechanism of action for the anti-tolerigenic properties of IL-6 by examining the signaling pathways downstream of IL-6R in primary human T cells. We show that in both effector and regulatory T cells, IL-6 preferentially signals through Stat3, with moderate activation of Stat1 and minimal MAPK/Erk activation. Inhibition of Stat3 signaling in mixed lymphocyte cultures containing IL-6 restores Treg-mediated suppression, demonstrating that IL-6-mediated loss of Treg suppression requires phosphorylation of Stat3. Criss-cross experiments, in which either effector or regulatory T cells were pre-treated with Stat3 inhibitors, show that pStat3 is required in both T cell populations for IL-6-mediated reversal of Treg function. Similarly, IL-21, which also signals preferentially through pStat3, induces a loss of Treg suppression, in contrast to signaling by IL-27 and IFNgamma, which signal preferentially through Stat1 and do not inhibit suppression. Lastly, effector T cells stimulated strongly through the TCR are resistant to suppression by Treg and have concurrent Stat3 phosphorylation; inhibition of pStat3 restores functional suppression by Treg. Collectively, our data suggest that Stat3 signaling is crucial for mediating effector cell resistance to Treg suppression and that kinase-specific inhibitors may hold therapeutic promise for the treatment of autoimmune disease.

ISBN: 9781124505602Subjects--Topical Terms:

1017854
Health Sciences, Pathology.

IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells.
LDR:03088nam 2200265 4500 001 1405503
005 20111219143041.5
008 130515s2011 ||||||||||||||||| ||eng d
020 $a 9781124505602
035 $a (UMI)AAI3446480
035 $a AAI3446480
040 $a UMI $c UMI
100 1 $a Goodman, Wendy Ann. $3 1684871
245 1 0 $a IL-6 signals through pStat3 to prevent functional immune suppression by human regulatory T cells.
300 $a 123 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 2045.
500 $a Adviser: Robert Fairchild.
502 $a Thesis (Ph.D.)--Case Western Reserve University, 2011.
520 $a Human autoimmune diseases such as psoriasis, multiple sclerosis, and rheumatoid arthritis are characterized by systemic T cell dysfunction, resulting in chronically activated Th1 and Th17 cells which are insufficiently suppressed by regulatory T cells. The data presented herein demonstrate that the pro-inflammatory cytokine IL-6 directly inhibits human regulatory T cell function, similar to its functions in the mouse. IL-6 is over-expressed in tissue and serum of patients with autoimmune diseases and is produced in high amounts by dermal dendritic cells and endothelial cells in the lesional skin of psoriasis patients. Upon T cell entry to the lesional skin, cells are exposed to high levels of IL-6, which likely contribute to their escape from regulation by Treg cells. We sought to determine the mechanism of action for the anti-tolerigenic properties of IL-6 by examining the signaling pathways downstream of IL-6R in primary human T cells. We show that in both effector and regulatory T cells, IL-6 preferentially signals through Stat3, with moderate activation of Stat1 and minimal MAPK/Erk activation. Inhibition of Stat3 signaling in mixed lymphocyte cultures containing IL-6 restores Treg-mediated suppression, demonstrating that IL-6-mediated loss of Treg suppression requires phosphorylation of Stat3. Criss-cross experiments, in which either effector or regulatory T cells were pre-treated with Stat3 inhibitors, show that pStat3 is required in both T cell populations for IL-6-mediated reversal of Treg function. Similarly, IL-21, which also signals preferentially through pStat3, induces a loss of Treg suppression, in contrast to signaling by IL-27 and IFNgamma, which signal preferentially through Stat1 and do not inhibit suppression. Lastly, effector T cells stimulated strongly through the TCR are resistant to suppression by Treg and have concurrent Stat3 phosphorylation; inhibition of pStat3 restores functional suppression by Treg. Collectively, our data suggest that Stat3 signaling is crucial for mediating effector cell resistance to Treg suppression and that kinase-specific inhibitors may hold therapeutic promise for the treatment of autoimmune disease.
590 $a School code: 0042.
650 4 $a Health Sciences, Pathology. $3 1017854
690 $a 0571
710 2 $a Case Western Reserve University. $b Pathology. $3 1675658
773 0 $t Dissertation Abstracts International $g 72-04B.
790 1 0 $a Fairchild, Robert, $e advisor
790 $a 0042
791 $a Ph.D.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3446480